CMS Unveils RAPID Pathway: A Game-Changer for Breakthrough Device Coverage and Medical Billing

In a move set to reshape the landscape of healthcare innovation and revenue cycle management, the Centers for Medicare & Medicaid Services (CMS) and the Food and Drug Administration (FDA) have introduced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway. First announced in April 2026 and formalized through a procedural notice on August 11, 2026, the RAPID pathway aims to drastically reduce the wait time for Medicare beneficiaries to access life-changing medical technologies.

With public comments open until October 10, 2026, medical coders, billers, and device manufacturers must understand how this new framework will impact Medicare NCD billing guidelines and the broader reimbursement ecosystem.

What is the RAPID Coverage Pathway?

Historically, medical device manufacturers faced a frustrating "valley of death" between securing FDA market authorization and obtaining a Medicare National Coverage Determination (NCD)—a gap that typically spanned 9 to 12 months.

Under the RAPID framework, CMS and the FDA will collaborate earlier in the device development lifecycle, specifically during the Investigational Device Exemption (IDE) pre-submission stage. By aligning clinical evidence expectations before FDA approval, CMS aims to issue a proposed NCD on the exact same day a device receives FDA market authorization.

"FDA and CMS each play a critical role in getting new medical devices to patients, and they work most effectively when aligned sooner in that process," stated CMS Administrator Dr. Mehmet Oz during the initial announcement. FDA Commissioner Dr. Marty Makary echoed this sentiment, emphasizing that the agencies are functioning as a "single team" to eliminate red tape.

Under RAPID, a final NCD could be issued within approximately 60 days for eligible Class II FDA-designated Breakthrough Devices participating in the FDA’s Total Product Life Cycle Advisory Program (TAP), and within 90 days for eligible Class III Breakthrough Devices.

The Coding and Billing Impact

For healthcare facilities and revenue cycle professionals, the RAPID pathway represents a paradigm shift. Faster Medicare coverage means a quicker transition from unlisted or miscellaneous codes to specific HCPCS Level II codes for breakthrough devices.

During the IDE clinical trial phase, coders will continue to rely on ICD-10-CM coding for investigational devices. For instance, encounters for